The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...
The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...
Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — warrants further investigation, according to researchers.
The Cytomegalovirus (CMV) Infection market growth is driven by factors like increase in the prevalence of Cytomegalovirus ...
On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term ...
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...
8h
GlobalData on MSNJ&J reports positive topline outcomes from Phase III NSCLC combo therapy trialJohnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.
The phase 4 PADMA study showed meaningful improvements in TFF and PFS in patients with high-risk HR-positive/HER2-negative metastatic breast cancer.
The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results